Table 1.

European Society of Cardiology (ESC) Guideline for the Use of Pharmacotherapy During Myocardial Revascularisation in Non ST Elevation Acute Coronary Syndrome (NSTEACS) which Includes NSTEMI and Unstable Angina [36]

NSTEMI		Class of Recommendation	Level of Evidence
Antiplatelet therapy
	Aspirin	I	C
	Clopidogrel (with 600 mg loading as soon as possible)	I	C
	Clopidogrel (for 9-12 months afterPCI)	I	B
	Prasugrel	IIa	B
	Ticagrelor	I	B
	GPI (in patients with evidence of high intracoronary thrombus burden)
	Abciximab (with DAPT)	I	B
	Tirofiban, eptifibatide	IIa	B
	Upstream GPI	III	B
Anticoagulation
Very high risk of ischaemia	UFH (+GPI) or	I	C
	Bivalirudin monotherapy	I	B
Medium-high risk of ischaemia	UFH	I	C
	Bivalirudin	I	B
	Fondaparinux	I	B
	Enoxaparin	IIa	B
Low risk of ischaemia	Fondaparinux	I	B
	Enoxaparin	IIa	B

Adapted from 2010 ESC “Guidelines on myocardial revascularisation”: ASA- Aspirin, GPIIb-IIIa - Glycoprotein IIb/IIIa, DAPT- dual antiplatelet therapy, UFH- unfractionated heparin